Last checked at (Sharecast News) - Pharmaceutical group Shield Therapeutics named Hans Peter Hasler as non-executive chairman of the company on Tuesday.
Shield tapped Hasler for the role after current chairman James Karis informed the group that he would not be seeking re-election at its upcoming annual general meeting on 18 June.
Hasler, who will take on the role after the AGM, was previously chief operating officer at both Elan Corporation and Biogen, as well as chief marketing officer of Wyeth Pharmaceuticals.
Chief executive Tim Watts said: "I am very pleased to see Hans Peter appointed as our chairman. I have worked increasingly closely with Hans Peter over the last two years and value his experience and insights and the support he has given me personally."
As of 0855 BST, Shield shares were down 1.56% at 91.06p.
19 Sep 2018 08:36
Shield Therapeutics irons losses, agrees commercialisation deal
(Sharecast News) - Iron deficiency treatment specialist Shield Therapeutics narrowed losses as revenues grew in the first half of that saw a series of positive developments.
Read more